IP Library Patent Application 17240273
Patent Application
App. No. 17/240,273

TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/240,273
Abstract

The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided.

Claims (15)

1 . A method for treating an acute or chronic inflammation of at least a portion of a respiratory tract in a subject in need thereof, the method comprising administering to the subject an aerosol of a solution comprising from about 90 mg/ml to about 110 mg/ml of levofloxacin and from about 190 mM to about 210 mM of a magnesium cation, a calcium cation, a zinc cation, a copper cation, an aluminum cation, or an iron cation; to treat the inflammation.

2 . The method of claim 1 , wherein the solution comprises about 100 mg/ml of levofloxacin and about 200 mM of the magnesium cation.

3 . The method of claim 2 , wherein the magnesium cation is in the form of magnesium chloride.

4 . The method of claim 1 , wherein the solution has a pH from about 5 to about 8 and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg.

5 . The method of claim 1 , wherein the aerosol has a mass median aerodynamic diameter from about 2 microns to about 5 microns with a geometric standard deviation less than or equal to 2.5 microns

6 . A method for treating a pulmonary inflammation in a subject in need thereof, the method comprising administering to the subject an aerosol of a solution comprising from about 90 mg/ml to about 110 mg/ml of levofloxacin and from about 190 mM to about 210 mM of a magnesium cation, a calcium cation, a zinc cation, a copper cation, an aluminum cation, or an iron cation; to treat the pulmonary inflammation.

7 . The method of claim 6 , wherein the pulmonary inflammation is an acute or chronic inflammation of a lung.

8 . The method of claim 6 , wherein the pulmonary inflammation is an acute or chronic inflammation of an upper airway,

9 . The method of claim 6 , wherein the solution comprises about 100 mg/ml of levofloxacin and about 200 mM of the magnesium cation.

10 . The method of claim 9 , wherein the magnesium cation is in the form of magnesium chloride.

11 . The method of claim 6 , wherein the solution has a pH from about 5 to about 8 and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg.

12 . A method for treating a pulmonary inflammation in a subject in need thereof, the method comprising administering to the subject a solution comprising from about 90 mg/ml to about 110 mg/ml of levofloxacin and from about 190 mM to about 210 mM of a magnesium cation, a calcium cation, a zinc cation, a copper cation, an aluminum cation, or an iron cation; to treat the pulmonary inflammation; wherein the subject does not have a pulmonary bacterial infection.

13 . The method of claim 12 , wherein the solution comprises about 100 mg/ml of levofloxacin and about 200 mM of the magnesium cation.

14 . The method of claim 13 , wherein the magnesium cation is in the form of magnesium chloride.

15 . The method of claim 12 , wherein the solution has a pH from about 5 to about 8 and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2021
From: DUDLEY, MICHAEL N; TSIVKOVSKI, RUSLAN Y; GRIFFITH, DAVID C; RODNY, OLGA
To: MPEX PHARMACEUTICALS, INC.
Reel/Frame 056411/0382 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2021
From: MPEX PHARMACEUTICALS, INC.
To: TRIPEX PHARMACEUTICALS, LLC
Reel/Frame 056383/0920 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2021
From: TRIPEX PHARMACEUTICALS, LLC
To: RAPTOR PHARMACEUTICALS INC.
Reel/Frame 056422/0235 →
CHANGE OF NAME Recorded May 28, 2021
From: RAPTOR PHARMACEUTICALS INC.
To: HORIZON ORPHAN LLC
Reel/Frame 056424/0102 →